Breaking News

inVentiv Appoints President and EVP

June 4, 2015

CRO industry veteran McKelvey to head Clinical and Health divisions

Michael McKelvey, Ph.D., has been appointed president, inVentiv Health Clinical Division and executive vice president, inVentiv Health. Dr. McKelvey has extensive experience in the CRO industry and a strong background in clinical development, technology and the development of industry strategies.
 
Dr. McKelvey previously served as executive vice president and chief operating officer at Aptiv Solutions, which was acquired by ICON in 2014. Prior to Aptiv Solutions, he was president and chief executive officer and a board member of eResearchTechnology, Inc. (ERT). Dr. McKelvey also led PAREXEL’s Phase II-IV clinical operations for the Americas, as well as their global data management and global biostatistics groups.
 
“Mike McKelvey has proven himself to be a hands-on leader who builds dynamic teams to tackle some of the most critical drug development issues facing the industry,” said Jeffrey P. McMullen, Chairman, inVentiv Health Clinical Division and Vice Chairman, inVentiv Health. “His vision is to incorporate innovation into the current drug development process by providing clients with an outsourcing model that embeds both clinical and commercial services.”

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems